首页> 外国专利> PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT

PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT

机译:包含血管紧张素-(1-9)的药物组合物,用于心血管,肺和/或脑的治疗

摘要

The invention relates to a pharmaceutical composition containing an effective quantity of angiotensin-(1-9) or derivatives thereof and at least one pharmaceutically acceptable carrier, excipient, stabilising agent, diluent and/or adjuvant. In addition, the invention relates to the use of the pharmaceutical composition and peptide angiotensin-(1-9), or peptides derived therefrom which are biological or chemical analogues, for the production of drugs that can be used to prevent, reverse, inhibit and/or reduce cardiovascular, pulmonary, cerebral or renal remodeling.; The invention further relates to a method for preventing, reversing, inhibiting and/or reducing cardiovascular, pulmonary, cerebral or renal remodeling, consisting of raising the concentration of peptide angiotensin-(1-9) or peptides derived therefrom in the blood and/or tissues, using a pharmaceutical composition containing a vector expressing ECA2, the enzyme responsible for the endogenous production of angiotensin-(1-9). Said vectors correspond to adenoviruses, retroviruses, lentiviruses or adeno-associated viruses containing the gene that codes for ECA2.; The invention can be used for the administration of angiotensin-(1-9) or derivatives thereof in oral form, in injectable form or by means of continuous pump infusion or to raise the levels of same in the body by means of treatment with: angiotensin-I-converting-enzyme inhibitors, angiotensin II (ARA II) receptor antagonists, Rho kinase inhibitors, antagonists of the calcium L-channels and/or diuretics.
机译:本发明涉及包含有效量的血管紧张素-(1-9)或其衍生物和至少一种药学上可接受的载体,赋形剂,稳定剂,稀释剂和/或佐剂的药物组合物。另外,本发明涉及药物组合物和作为生物或化学类似物的肽血管紧张素-(1-9)或由其衍生的肽在制备可用于预防,逆转,抑制和抑制药物的药物中的用途。 /或减少心血管,肺,脑或肾的重塑。本发明进一步涉及预防,逆转,抑制和/或减少心血管,肺,脑或肾重塑的方法,其包括提高血液和/或血液中的肽血管紧张素-(1-9)或由其衍生的肽的浓度。在组织中,使用含有表达ECA2的载体的药物组合物,该酶负责内源性血管紧张素-(1-9)的产生。所述载体对应于含有编码ECA2的基因的腺病毒,逆转录病毒,慢病毒或腺伴随病毒。本发明可用于以口服形式,可注射形式或通过连续泵输注的方式施用血管紧张素-(1-9)或其衍生物,或通过以下方式治疗以提高体内的血管紧张素-(1-9)或其衍生物的水平: -I转化酶抑制剂,血管紧张素II(ARA II)受体拮抗剂,Rho激酶抑制剂,钙L通道拮抗剂和/或利尿剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号